Table 1: Convergent Procedure Studies.
| Studies | Type | Year | Type of AF (PAF, PsAF, LSPAF) | Timeframe of Treatment | No. of Patients | Timing | Mortality | Complications | Follow-up | Freedom from AF ± Antiarrhythmics (%) | Freedom from any Atrial Arrhythmia ± Antiarrhythmics (%) | Freedom from any Atrial Arrhythmia off Antiarrhythmics (%) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Transabdominal without AtriClip | ||||||||||||
| Kiser et al.[46] | Observational | 2011 | PAF, PsAF, LSPAF | Jan 2009-May 2010 | 65 | Concomitant | 5% | 8% | 12 months | – | 88% | 83% |
| Zembala et al.[47] | Observational | 2012 | PsAF, LSPAF | Aug 2009-Dec 2011 | 27 | Staged | 3.7% | 10% | 12 months | 80% | – | – |
| Gehi et al.[48] | Observational | 2013 | PAF, PsAF, LSPAF | Jan 2009-Dec 2011 | 101 | Concomitant | 0% | 6% | 12 months | 73% | – | – |
| Civello et al.[76] | Observational | 2013 | PAF, PsAF, LSPAF | May 2010-Dec 2011 | 104 | Concomitant | 0% | 6% | 12 months | – | 87.5% | 72% |
| Thosani et al.[54] | Observational | 2013 | PsAF, LSPAF | Jun 2010-Feb 2013 | 43 | Concomitant | 0% | 0% | 6 months | – | 89% | – |
| Gersak et al.[51] | Observational | 2014 | PsAF;, LSPAF | Jan 2010-Dec 2011 | 73 | Concomitant | 0% | 7% | 12 months | 73% | – | – |
| Edgerton et al.[50] | Prospective | 2016 | LSPAF | – | 24 | Concomitant | 14% | 7% | 24 months | 19% | – | – |
| Gersak et al.[49] | Observational | 2016 | PAF, PsAF, LSPAF | Jan 2009-Jul 2013 | 76 | Concomitant & staged | 0% | 12% | 48 months | – | 81% | 69% |
| Zembala et al.[55] | Prospective | 2017 | PsAF, LSPAF | Jul 2009-Dec 2014 | 90 | Staged | 1% | 8% | 12 months | – | 82% | 62% |
| Kress et al.[52] | Observational | 2017 | PsAF, LSPAF | Jun 2010-Aug 2014 | 64 | Concomitant | 1.6% | 7.8% | 16 months | 72% | – | |
| Jan et al.[77] | Randomised | 2018 | PAF Jan 2013-Jun 2015 | 24 | Concomitant | 0% | 12.5% | 30.5 months | – | – | 58.3% | |
| Gulkarov et al.[78] | Observational | 2019 | PsAF, LSPAF | Oct 2013-Mar 2017 | 31 | Concomitant | 0% | 12.9% | 24 months | 71% | 52% | – |
| Subxiphoid without AtriClip | ||||||||||||
| Gegechkori et al.[71] | Observational | 2019 | PsAF, LSPAF | Jan 2014-Aug 2016 | 59 | Concomitant | 0% | 1.6% | 12 months | – | 76% | – |
| Sabzwari et al.[79] | Observational | 2019 | LSPAF | Feb 2015-Sept 2017 | 30 | – | 0% | 0% | 12 months | 80% | – | 63% |
| Subxiphoid with AtriClip | ||||||||||||
| Gegechkori et al.[71] | Observational | 2019 | PsAF, LSPAF | Aug 2016-Oct 2019 | 64 | Concomitant | 0% | 7.8% | 12 months | – | 87.5% | – |
| Tonks et al.[72] | Observational | 2019 | PAF, PsAF, LSPAF | Feb 2016-May 2017 | 36 (25/36 subxiphoid, 13/36 with AtriClip) | Concomitant (32/36) | 0% | 16.7% | 12 months | – | 78% | – |
LSPAF = longstanding persistent AF; PAF = paroxysmal AF; PsAF = persistent AF.